Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended											2 Months Ended	12 Months Ended									151 Months Ended			1 Months Ended								12 Months Ended		1 Months Ended	12 Months Ended		1 Months Ended										1 Months Ended		12 Months Ended			1 Months Ended				1 Months Ended		1 Months Ended								1 Months Ended		2 Months Ended	1 Months Ended					5 Months Ended	1 Months Ended			1 Months Ended
	Mar. 31, 2013	Aug. 22, 2012	Aug. 07, 2012	Sep. 28, 2011	May 31, 2011	Mar. 31, 2011	Jul. 31, 2006	Dec. 31, 2003	Nov. 30, 2003	Jun. 30, 2003	May 31, 2002	Aug. 31, 2011	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011	Jun. 30, 2009	Jun. 30, 2008	Jun. 30, 2007	Jun. 30, 2004	Jun. 30, 2003	Jun. 30, 2002	Jun. 30, 2013	Apr. 30, 2011	Dec. 18, 2006	Dec. 31, 2011 Securities Subscription Agreement With Novogen	Dec. 28, 2011 Securities Subscription Agreement With Novogen	Sep. 27, 2011 Securities Subscription Agreement With Novogen	Sep. 30, 2011 Securities Subscription Agreement With Novogen	Mar. 31, 2011 Series B Preferred Stock	Dec. 31, 2012 Series A warrants	Sep. 28, 2011 Series A warrants	May 31, 2011 Series A warrants	Jun. 30, 2012 Series A warrants	Jun. 30, 2013 Series A warrants	Sep. 28, 2011 Series B warrants	Jun. 30, 2012 Series B warrants	Jun. 30, 2013 Series A Preferred Stock	Aug. 31, 2007 Placement Agent	May 31, 2012 Novogen	Nov. 20, 2012 Novogen Series A Preferred Stock	Aug. 31, 2007 Accredited Investors	Jul. 31, 2008 Accredited Investors Securities Subscription Agreement With Novogen	Mar. 31, 2011 First Anniversary Series B Preferred Stock	Mar. 31, 2011 Redeemed on or after the first anniversary but prior to the second anniversary of the Series B Initial Issuance Date Series B Preferred Stock	Mar. 31, 2011 Redeemed on or after the second anniversary but prior to the third anniversary of the Series B Initial Issuance Date Series B Preferred Stock	Mar. 31, 2011 Redeemed on or after the third anniversary but prior to the fourth anniversary of the Series B Initial Issuance Date Series B Preferred Stock	Mar. 31, 2011 Upon or after the fourth anniversary of the Series B Initial Issuance Date Series B Preferred Stock	Apr. 30, 2011 Maximum	Mar. 31, 2011 Upon the Company's liquidation, dissolution or winding up Series B Preferred Stock	Jun. 30, 2013 Conversion Condition 1 Series A Preferred Stock	Jun. 30, 2013 Conversion Condition 2 Series A Preferred Stock	Dec. 05, 2012 Warrants Cancelled Novogen	Mar. 31, 2011 Stock Purchase Agreement	Mar. 31, 2011 Stock Purchase Agreement Series B Preferred Stock	May 11, 2012 Rights Offering	Jun. 30, 2013 Rights Offering	Mar. 30, 2012 Rights Offering Maximum	May 11, 2012 Rights Offering Subscription Rights	Dec. 29, 2011 Amended Purchase Agreement	May 31, 2011 Amended Purchase Agreement	May 31, 2011 Amended Purchase Agreement Series A warrants	May 31, 2011 Amended Purchase Agreement Series B warrants	May 11, 2011 Amended Purchase Agreement Series B warrants	May 31, 2011 Amended Purchase Agreement Placement Agent	May 31, 2011 Amended Purchase Agreement Maximum	May 11, 2011 Amended Purchase Agreement Maximum	May 31, 2011 Amended Purchase Agreement Maximum Series A warrants	May 31, 2011 Amended Purchase Agreement Minimum	Mar. 31, 2011 At Market Issuance Sales Agreement	Feb. 28, 2011 At Market Issuance Sales Agreement Maximum	Jul. 31, 2006 Equity Distribution Agreement	Dec. 18, 2012 Private Placement	Jul. 31, 2008 Private Placement	Jul. 31, 2006 Private Placement	Apr. 30, 2013 Private Placement	Dec. 29, 2011 Private Placement Amended Purchase Agreement	Apr. 10, 2013 Underwritten Registered Offering	Jun. 30, 2013 December 2012 private placement	May 31, 2002 Initial Public Offering
Class of Stock [Line Items]
stock issued								239,200				215,667													323,625			222,222		194,381					50,934				749,056		91,067	28,333											107,391	742	971,700				111,212	139,203									9,200			9,166,665		105,488		40,950	2,030,000		42,050
Purchase price common stock								$ 75.00																	$ 6.18			$ 9.00													$ 180.00																			$ 8.00																	$ 7.50
Proceeds from issuance of common stock											$ 9,000,000		$ 39,453,000	$ 9,831,000								$ 126,387,000			$ 2,000,000	$ 2,000,000	$ 2,000,000	$ 2,000,000																									$ 1,001,700		$ 4,800,000														$ 45,000								$ 14,200,000
Warrants issued																																						1,035	374,528																485,857									35,008								6,416,665							42,050
Aggregate Offer price of stock																																																																								27,500,000
Proceed from issuance of private placement							16,800,000																																		15,200,000	9,800,000																														25,300,000
Warrants exercised																																																																											1,890,304
Common stock issued upon exercise of warrants																																																																											1,383,959
Issuance of common stock to acquire intellectual property and technology rights		500,000	500,000
Issuance of common stock to purchase asset, shares		195,756
Warrants to purchase common stock																																																				166,666					17,129,361
Aggregate purchase price of subscription rights																																																									7,600,000
Number of shares of common stock in each unit							1	0.17																																															0.0833
Number of shares each warrant to purchase of common stock								0.17																																	0.67														0.04167
Exercise price									240.00				130.20									130.20		540.00										6.00					7.14		216.00	130.20													7.14	7.14																						3.12
Purchase price																																																										0.445
Share price																																																						$ 1,000				$ 5.34
Number of subscription right unit issued																																							8,988,675																11,660,606
Investment warrants, exercisable period																																6 months							5 years																5 years
Warrants exercised	41								41,900	150
Warrants exercisable												161,750																			108,942				145,256																										104,402	360,922					375,094						768	36,921
Price of common stock																																																																	$ 8.00	$ 8.00		$ 4.50
Limit of issuable shares																																																																	388,764			108,207
Investment warrants exercise price																															$ 6.00	$ 9.42						$ 180.00																																			$ 130.20
Amount equivalent of the number of shares of common stock issued on exercise of series B warrants																																75.00%
Expiration period of warrants																																5 years
Exercise price description																																																															The initial exercise price per share of the Series B warrants was equal to the lower of (i) $8.00, and (ii) 85% of the arithmetic average of the lowest eight weighted average prices of the common stock during the 20 consecutive trading day period in the case of a voluntary exercise by the holders, ending on the trading day immediately preceding the date of delivery of a notice of exercise.
Proceeds from exercise of warrants									10,100,000	36,000		1,094,000
Warrants outstanding													768									768												215,721	0																					319,150																						4,526,361
Common stock issued upon exercise of warrants																														119,158
Cash payments to investors in aggregate amount				365,000
Payment for financing Costs				41,000										406,000								406,000
Derivative liabilities					1,174,000										1,125,000
Excess of fair value of derivative liabilities over proceeds of private placement					666,000
Liabilities in excess of the proceeds					508,000
Gain on adjustment to fair value of derivative liabilities														1,139,000	49,000							1,188,000											14,000			1,125,000
Sale of shares and warrants under agreement																																																50,000,000
Public float maximum value																							75,000,000
Receivable secured full-recourse promissory notes																																																					1,001,700
Bearing interest rate for promissory notes																																																					2.00%
Net proceeds from issuance of preferred stock																						665,000																																742,000
Net proceeds from issuance of common stock and warrants						665,000		15,500,000
Shares issued to related party																																										48,472
Sales of common stock offer price																																																																						1,815,000
Stock Issued during period, value, new issues													39,453,000	9,831,000		9,768,000	14,727,000	16,820,000	25,578,000	36,000	9,022,000																																																131,000
Number of shares exercised under warrants																																									1.67
Basis of exercise of warrants																																						4
Fair value of warrants																																						441,000
Commitment fee paid in shares																																																																							2,060
Commitment fee paid in warrants																																																																							10,000
Exercise price of warrants expired without exercise							$ 261.00																																																																$ 261.00
Purchase price per unit under private placement							$ 29.00
Number of warrants in each unit							0.06	1
Warrants expired without exercise								239,200
Total authorized share capital													113,100,000									113,100,000
Common stock, shares authorized													113,000,000	113,000,000								113,000,000
Common stock, par value													$ 0.00000002	$ 0.00000002								$ 0.00000002
Preferred stock, shares authorized													100,000	100,000								100,000
Preferred stock, par value per share													$ 0.01	$ 0.01								$ 0.01
Company designated and issued shares to Isoflavone																																					1,000
Each share of Convertible Preferred Stock issued, converted into common stock																																																		804.5	1,609
Common stock issued up on Conversion of preferred stock																																								804,500
Number of redeemable preferred stock																													742
Dividend receivable, percentage																													10.00%
Redemption price percentage																																											135.00%	126.00%	117.00%	108.00%
Redemption principal amount																																											$ 1,000				$ 1,000		$ 1,000